GlassScriptPhysician profile
Autumn Ward
NPI 1093119505
$2,698.29
in general payments reported to CMS, 2019-2025
19 companies · $998 in 2025
The $998 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $445 · 2022: $327 · 2023: $367 · 2024: $561 · 2025: $998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,925.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,419.96 | 2021-2025 | |
| Madrigal Pharmaceuticals | $270.16 | 2024-2025 | Rezdiffra, Resmetirom |
| Medtronic, INC. | $146.39 | 2021 | |
| Phathom Pharmaceuticals, INC. | $115.62 | 2025 | Voquezna |
| Qol Medical, LLC | $89.08 | 2022-2025 | Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $82.12 | 2021-2025 | Gattex, Entyvio |
| Aimmune Therapeutics, INC. | $80.63 | 2024-2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.96 | 2022-2025 | Xifaxan |
| Organon LLC | $60.52 | 2022-2025 | Hadlima |
| Ipsen Biopharmaceuticals, INC | $58.66 | 2024-2025 | Iqirvo, Bylvay |
| Mallinckrodt Hospital Products INC. | $55.82 | 2024-2025 | Terlivaz |
| Daiichi Sankyo INC. | $54.29 | 2022-2023 | Injectafer |
| Lilly USA, LLC | $45.20 | 2024 | Omvoh |
| Ferring Pharmaceuticals INC. | $42.25 | 2022-2023 | Rebyota |
| Evoke Pharma, INC. | $34.82 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $25.13 | 2023 | |
| Amag Pharmaceuticals, INC. | $19.39 | 2022 | |
| Ardelyx, INC. | $18.12 | 2024 | Ibsrela |
| Celgene Corporation | $17.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Autumn Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.